Graham Holdings Company Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Graham Holdings Company Common Stock trades at $1,186.01 (market cap $5.02B), while Roivant Sciences Ltd. Common Shares trades at $33.68 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 5× Graham Holdings Company Common Stock's market cap, and Graham Holdings Company Common Stock pays a 0.63% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Graham Holdings Company Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| GHC | ROIV | |
|---|---|---|
Market Cap | $5.02B | $24.99B |
Volume | 21,118 | 4,711,562 |
Sector | Industrials | Health |
52-Week High | $1.23K | $41.81 |
52-Week Low | $949.84 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $5.12B | $21.25B |
Dividend Yield | 0.63% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Graham Holdings Company is a diversified holding company with operations spanning education services (Kaplan), television broadcasting (Graham Media Group), healthcare services, and manufacturing, among other businesses; it was formerly known as The Washington Post Company.
Read more on GHC →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →